Results 101 to 110 of about 27,373 (254)

Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System [PDF]

, 2016
Aim: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil.
Acurcio, Francisco De Assis, Almeida, Alessandra Maciel, Alvares, Juliana, Bennie, Marion, De Oliveira, Haliton Alves, Dos Santos, Jéssica Barreto Ribeiro, Godman, Brian, Guerra, Augusto Afonso, Kakehasi, Adriana Maria   +8 more
core   +1 more source

Evaluation of impaired growth plate development of long bones in skeletally immature mice by antirheumatic agents. [PDF]

J Orthop Res, 2021
Caron MMJ, van Rietbergen B, Castermans TMR, Haartmans MJJ, van Rhijn LW, Welting TJM, Witlox AMA.   +6 more
europepmc   +1 more source

Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis within a Longitudinal Cohort

Arthritis &Rheumatology, Accepted Article.
Objective To estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axSpA and to identify factors associated with D2M/TR disease in a longitudinal cohort. Methods We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis Program cohort.
Patricia Remalante‐Rayco, Laura Passalent, Tina Chim, Hannah Vijayan, Manal Alnasser, Zeynep Baskurt, Robert D. Inman, Nigil Haroon, Denis Poddubnyy   +8 more
wiley   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, EarlyView.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries : are differences related to country's wealth? [PDF]

, 2014
Objectives: To explore criteria regulating treatment with reimbursed biologic disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) across Europe and to relate criteria to indicators of national socioeconomic welfare.
Boonen, Annelies, Equity in Clinical Eligibility Criteria for RA treatment Working group, on behalf of, Kvien, Tore K, Mielants, Herman, Putrik, Polina, Ramiro, Sofia, Sokka, Tuulikki, Uhlig, Till   +7 more
core   +2 more sources

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source

The Incidence and Risk Factor Analysis of Drug Induced Liver Injury (Dili) in a Surabaya Hospital [PDF]

, 2018
The research has been conducted on the incident and analysis of risk factors drug liver injury (DILI) in a Surabaya Hospital. The aim of this study was to determine the incident of DILI, know which drugs cause DILI, and see the association of risk ...
Arrang, S. T. (Sherly), Widyati, W. (Widyati)   +1 more
core  

A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration : the Be-Raise study [PDF]

, 2016
Objectives : Biological treatment of rheumatoid arthritis (RA) is one of the cornerstones of current treatment strategies for the disease. Surprisingly little information exists on whether the route of administration affects patients' treatment ...
Bert Vander Cruyssen, Dirk Elewaut, Herman Mielants, Jan Lenaerts, null null, Patrick Durez, René Westhovens, Sophie De Mits   +7 more
core   +4 more sources

Trial of a new antirheumatic agent.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1974
A double-blind crossover trial of fenoprofen calcium versus acetylsalicylic acid (aspirin) and placebo in 10 outpatients with active rheumatoid arthritis, is reported. Both fenoprofen and aspirin were found to be similarly effective agents in rheumatoid arthritis with an average dose of 2,1 g fenoprofen compared with 4,5 g aspirin.
openaire   +3 more sources